TABLE 1.

Overview of clinical trials involved in FGFR4 inhibitors.

Drug	Clinical trial ID	Target(s)	Study design	Tumor types	Phase	Primary endpoint	Status
Ponatinib	NCT02428543	Multipul RTKs, including Pan-FGFRs	40 participants Single group assignment Open label	Acute myeloid lukemia	I/II	Treatment	Recruiting
Erdafitinib JNJ -42756493	NCT03827850	Pan-FGFRs	50 participants Parallel assignment Open label	Squamous non-small cell lung carcinoma	II	ORR	Recruiting
FGF401	NCT02325739	FGFR4	172 participants Single group assignment Open label	HCC	I	Incidence rate of dose-limiting toxicity (DLT)	Completed
BLU-554	NCT02508467	FGFR4	150 participants Single group assignment Open label	HCC	I	Maximum tolerated dose (MTD) on qd and bid schedules	Recruiting
H3B6527	NCT0342457	FGFR4	17 participants Single group assignment Open label	Healthy participants	I	Mean area under the plasma-concentration time curve from time 0 through the last measurable concentration (AUC0-t) of H3B-6527	Completed
H3B6527	NCT02834780	FGFR4	128 participants Single group assignment Open label	Advanced hepatocellular carcinoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma	I	Number of participants with dose-limiting toxicities (DLTs) [time frame: escalation cycle 1 (21 days)]	Recruiting
INCB062079	NCT03144661	FGFR4	100 participants Parallel assignment Open label	Hepatocellular carcinoma (HCC), cholangiocarcinoma, esophageal cancer	I	Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs)	Recruiting